Prediagnostic use of low‐dose aspirin and risk of incident metastasis and all‐cause mortality among patients with colorectal cancer

In real‐world, population‐based study (n=7478, Italy), prediagnostic use of low‐dose aspirin was not linked to decreased risk of incident metastasis (HR 0.88; 95% CI 0.63–1.22) or all‐cause mortality (1.09; 0.96–1.22) compared with no use, in patients with colorectal cancer.

Source:

British Journal of Clinical Pharmacology